Trastuzumab Infusion Reactions: Characteristics and Management
Trastuzumab infusion reactions are common (20-40% of patients on first infusion) but typically mild, with severe reactions occurring in less than 1% of patients. 1
Incidence and Timing
The incidence of infusion reactions (IRs) with trastuzumab varies considerably:
- First infusion: 20-40% of patients experience reactions 1
- Severe reactions: Less than 1% 1
- Subsequent infusions: Incidence decreases significantly 1
Most reactions occur during or within 24 hours of the first infusion 2. Unlike rituximab (77% IR rate) or cetuximab (90% IR rate), trastuzumab has a more moderate IR profile 1.
Clinical Presentation
Common symptoms include:
- Chills and fever (most frequent)
- Blood pressure changes (hypo- or hypertension)
- Bronchospasm
- Itching
- Dyspnea and wheezing
- Cardiac arrhythmia
- Angioedema 1
Severe reactions (rare) may manifest as anaphylaxis, severe bronchospasm, angioedema, or acute respiratory distress syndrome 2.
Mechanism
Trastuzumab is a humanized monoclonal antibody (IgG1) targeting HER2 1. The reactions are thought to result from cytokine release rather than true IgE-mediated hypersensitivity 1. This explains why reactions typically occur with the first infusion and decrease with subsequent doses, unlike true allergic reactions 1.
Management Algorithm
Prophylaxis
Routine premedication is NOT recommended by ESMO guidelines 1. However, recent evidence suggests dexamethasone premedication may reduce IR incidence from 60% to 24% 3.
Infusion timing:
- Loading dose: 90 minutes
- Subsequent doses: 30 minutes 1
During Infusion Reactions
Grade 1-2 (Mild to Moderate):
- Stop or slow the infusion rate immediately
- Provide symptomatic treatment
- Meperidine specifically for chills and rigors 1
- After complete symptom resolution, may resume at slower rate
- All patients can continue subsequent trastuzumab cycles 1
Grade 3-4 (Severe):
- Stop the infusion immediately
- Aggressive symptomatic treatment (epinephrine, corticosteroids, diphenhydramine, bronchodilators, oxygen as needed) 2
- Monitor until complete resolution of symptoms
- After resolution, may resume at slower rate unless the reaction was severe 1
- Strongly consider permanent discontinuation for severe reactions 2
Post-Reaction Management
Critical pitfall: Observe patients for several hours after severe reactions due to risk of biphasic reactions 1. Fatal reactions have occurred within hours to days following serious IRs 2.
For subsequent infusions after a reaction:
- Most patients who experienced severe IRs were premedicated with antihistamines and/or corticosteroids before rechallenge 2
- Some patients tolerated subsequent infusions; others had recurrent severe reactions despite premedications 2
- Only one patient in a series of 32 who experienced an IR had a subsequent reaction 4
Risk Factors
Factors associated with increased IR risk include:
- High tumor burden (large tumor volume, extensive disease) 5, 6
- Elevated alkaline phosphatase levels 6
- Low HDL cholesterol 6
- Concurrent pertuzumab use 6
- Higher body mass index 4
Clinical pearl: Patients with high tumor burden may benefit from premedication and extended infusion times for the first dose 5.
Key Distinctions from Other Monoclonal Antibodies
Unlike cetuximab (which requires premedication with corticosteroids plus antihistamines) or rituximab (which requires antipyretic and antihistamine premedication), trastuzumab does not require routine premedication 1. The vast majority of reactions are mild, easily managed, and do not recur with subsequent infusions 4, 7.